A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Corbus Pharmaceuticals Holdings, Inc.
CRBP
$40M
Mkt Cap
$9.17
-1.61%
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a 5-year average return on invested capital (ROIC) of -107.9%. This is below average and may indicate limited pricing power.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a market capitalization of $161M. It is classified as a small-cap stock.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) does not currently pay a regular dividend.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) generated $-36 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported earnings per share (EPS) of $-10.31 in its most recent fiscal year.
All references in this report to “Corbus,” the “Company,” “we,” “us,” or “our” mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates. Corbus Pharmaceuticals Holdings, Inc. (the “Company” or “Corbus”) is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ oncology pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, a next-generation antibody drug conjugate ("ADC") that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E ("MMAE") and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells.
| Metric | TTM | FY2023 | FY2022 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 36M | - | - |
| Net Income | -68M | -45M | -42M | -71M | -56M | -32M |
| EPS | $-5.49 | $-10.31 | $-10.15 | $-33.60 | $-29.40 | $-19.50 |
| Free Cash Flow | 0 | -36M | -38M | -48M | -32M | -29M |
| ROIC | -54.8% | -126.0% | -86.5% | -989.2% | -162.9% | -56.1% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.00 | 0.57 | 6.98 | 0.71 | 0.16 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -76M | -45M | -40M | -77M | -57M | -33M |
| Operating Margin | 0.0% | - | - | -213.3% | - | - |
| ROE | -73.3% | -342.0% | -128.4% | -424.3% | -202.3% | -56.1% |
| Shares Outstanding | 18M | 4M | 4M | 2M | 2M | 2M |
| Metric | ||||||||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | N/A | N/A | N/A | 36M | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -8.9M | -20M | -33M | -57M | -77M | -40M | -45M | -76M |
| Op. Margin | N/A | N/A | N/A | N/A | -213.3% | N/A | N/A | 0.0% |
| Net Income | -8.9M | -20M | -32M | -56M | -71M | -42M | -45M | -68M |
| Net Margin | N/A | N/A | N/A | N/A | -197.7% | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -98.5% | -177.0% | -56.1% | -162.9% | N/M | -86.5% | -126.0% | -54.8% |
| ROE | -98.5% | -224.2% | -56.1% | -202.3% | -424.3% | -128.4% | -342.0% | -73.3% |
| ROA | -68.7% | -111.8% | -48.4% | -118.5% | -148.7% | -63.9% | -94.3% | -61.6% |
| Cash Flow | ||||||||
| Op. Cash Flow | -4.6M | -14M | -28M | -30M | -46M | -38M | -36M | -60M |
| Free Cash Flow | -4.7M | -14M | -29M | -32M | -48M | -38M | -36M | 0 |
| Owner Earnings | -5.8M | -17M | -34M | -38M | -58M | -44M | -40M | -64M |
| CapEx | 114K | 353K | 707K | 2.3M | 2.7M | 13K | 0 | 0 |
| Maint. CapEx | 44K | 88K | 256K | 494K | 739K | 763K | 641K | 641K |
| Growth CapEx | 70K | 265K | 452K | 1.8M | 2.0M | 0 | N/A | 0 |
| D&A | 44K | 88K | 256K | 494K | 739K | 763K | 641K | 641K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.2M | 3.2M | 5.7M | 7.6M | 12M | 5.7M | 3.5M | 3.5M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 867K | 426K | 426K |
| Balance Sheet | ||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -40M | -5.0M | -104M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 104M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | 16M | 0 | N/A |
| Debt/Equity | 0.43 | 1.01 | 0.16 | 0.71 | 6.98 | 0.57 | 0.00 | 0.00 |
| Interest Coverage | -9062.1 | -41897.4 | -177.8 | -5437.2 | -2618.3 | -20.2 | -17.3 | -17.3 |
| Equity | 9.0M | 8.9M | 58M | 28M | 6.2M | 33M | -6.9M | 92M |
| Total Assets | 13M | 18M | 67M | 47M | 49M | 66M | 28M | 110M |
| Total Liabilities | 3.9M | 9.0M | 9.2M | 19M | 43M | 33M | 35M | 17M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -13M | -33M | -66M | -121M | -193M | -392M | -437M | -437M |
| Working Capital | 9.1M | 8.5M | 57M | 26M | 3.3M | 48M | -8.3M | -8.3M |
| Current Assets | 13M | 17M | 66M | 44M | 38M | 60M | 24M | 24M |
| Current Liabilities | 3.6M | 8.9M | 8.2M | 18M | 35M | 13M | 32M | 32M |
| Per Share Data | ||||||||
| EPS | -8.40 | -14.70 | -19.50 | -29.40 | -33.60 | -10.15 | -10.31 | -5.49 |
| Owner EPS | -5.53 | -12.37 | -20.30 | -20.16 | -27.48 | -10.55 | -9.29 | -3.62 |
| Book Value | 8.53 | 6.56 | 34.75 | 14.54 | 2.90 | 7.91 | -1.60 | 5.25 |
| Cash Flow/Share | -4.39 | -9.98 | -16.72 | -15.88 | -21.50 | -9.00 | -8.34 | -3.81 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.1M | 1.4M | 1.7M | 1.9M | 2.1M | 4.2M | 4.3M | 17.6M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.7 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 5.7 | 40.5 | 6.3 | 12.1 | 56.1 | 0.4 | N/A | 1.7 |
| Price/Sales | N/A | N/A | N/A | N/A | 11.1 | N/A | N/A | N/A |
| FCF Yield | -9.2% | -3.9% | -7.8% | -9.7% | -14.0% | -275.3% | -135.5% | N/A |
| Market Cap | 52M | 361M | 367M | 334M | 345M | 14M | 27M | 161M |
| Avg. Price | 73.51 | 117.58 | 213.21 | 191.84 | 188.78 | 8.62 | 6.38 | 9.17 |
| Year-End Price | 48.90 | 265.50 | 220.50 | 176.40 | 162.30 | 3.27 | 6.16 | 9.17 |
Corbus Pharmaceuticals Holdings, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a return on equity (ROE) of -342.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for Corbus Pharmaceuticals Holdings, Inc. (CRBP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a book value per share of $-1.60, based on its most recent annual SEC filing.